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SUMMARY
In 1982 the macrocyclic lactone, ivermectin, was first tested in human patients with onchocerciasis. It has since undergone phase I to IV trials and is now being widely Onchocerciasis is identified by the WHO as a major global public health problem and has been included as a target disease for active research within WHO's Special Pro gramme for Research and Training in Tropical Diseases (TDR). It is estimated that, worldwide, about 18 million individuals are infected with onchocerciasis with a further 68 million people at risk of infection.l The disease affects primarily the skin and eyes and may have a major socio economic impact through visual impairment; blindness prevalences exceeding 10% have been reported in heavily infected populations. 2 Measures for combating onchocerciasis include use of larvicides in rivers (to control the vector, Simulium dam-11 os lllll ) and drug therapy. Until recently therapy relied on two drugs: diethylcarbamazine citrate (DEC, Heterozan or Banocide) and suramin. Administration of the macrofil aricide suramin requires hospital admission and monitor ing since it is given intravenously in multiple weekly doses. It has a reversible nephrotoxicity that is used to monitor dosage and its use in the high doses recommended for onchocerciasis is associated with idiosyncratic reac tions including exfoliative dermatitis. diarrhoea, and even death. DEC has been the most frequently used drug in onchocerciasis. It is a microfilaricide that regularly pro duces a marked eosinophilic reaction (pruritis, and pap ular skin eruptions). This reaction was first described in Mexico by Mazzotti. who proposed its use as a sup plementary diagnostic aid for onchocerciasis. 1 This suggestion was taken up and the drug widely used, for both the diagnosis and the treatment of the disease. For many years the principal objections to the use of DEC were the dermatitis, lymphadenopathy. headache and ver tigo it produced. In the late 1970s, however, it was sug gested that the use of DEC might also result in impairment of vision. in particular, through the precipitation of optic atrophy.4.5 This effect was demonstrated conclusively in 1980 by Bird ct al.
b who found that treatment with DEC precipitated active optic neuritis in 9 of 18 patients, and worsened pre-existing optic neuritis in a further 3 patients. The macrocyclic lactone, ivermectin. has been used as an antihelminthic in cattle for many years. In 1982 iver mectin was tested in human patients with onchocerciasis 7 and found to reduce significantly the microfilarial counts in skin snips of infected individuals for periods of 6 months to I year. It has since undergone phase I to IV trials and is now being widely distributed to communities at risk of onchocercal infection. Ivermectin may cause a mild pruritis, sometimes with lymphadenopathy, especi ally in people with high microfilarial loads and, rarely, hypotensive episodes are seen.8 As well as the clearing of microfilariae from the skin, reductions in the presence of uveitis, limbitis and punctate keratitis have been reported. Y Few data are available concerning the effect of ivermectin on active optic neuritis. The trial reported here was designed to determine whether or not ivermectin pre cipitates or exacerbates active optic neuritis in the 7-14 day period following dosing. With DEC, optic neuritis is precipitated within 2-3 days. Our clinical experience has shown that the active optic neuritis associated with oncho cerciasis lasts from several weeks to 1 year or more. This time period of follow-up was therefore chosen in order to allow sufficient time for the neuritis to develop and not enough time for it to resolve following dosing.
METHODS
Thirty-four rural communities, in two areas of Kaduna State, Northern Nigeria, were selected for inclusion in the trial.lo In these communities the overall prevalence of onchocercal infection (as measured by skin-snip posit ivity) was 49% among those aged 5 years and above, and 72% among those aged 20 years and above. The com munity microfilarial load was 3.5 mf!mg skin. The vast majority of people in these communities live as subsist ence farmers. In 1988/9 an extensive ophthalmic screen ing examination was performed at a central location in each village, with the aim of examining all registered indi viduals according to a structured protocol and identifying all those with definite or suspected optic nerve disease. Individuals were examined by a team of six trained oph thalmic nurses who underwent a 4 week period of training to minimise inter-observer variation. The tests employed included:
Visual acuity: using single E optotypes at 6 m in available outdoor light, with spectacle correction if routinely worn.
Visual fields: Visual fields were assessed with counting fingers in four peripheral quadrants, a 6 mm white target in the paracentral field, and a test for colour desaturation.
Contrast sensitivity: Using the Arden grating, each eye was tested with plates 3 and 5 for the threshold of appreci ation of the sinusoidal pattern.
Colour vision: In view of the fact that a majority of the population tested were illiterate, the Birch colour vision test using shape recognition was used. Eight colour plates were used to test eyes for colour discrimination. Three plates tested red/green discrimination and five plates blue/ yellow discrimination.
Pupil assessment: The nurses employed the swinging light test to determine whether an afferent pupiliary defect was present in either eye.
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Optic disc appearance: Provided the ocular media were clear, all discs were assessed by the nurses through undi lated pupils for pallor or swelling of the nerve head.
In addition the nurses examined the external eye, cornea, iris and lens.
The normal ranges for the colour vision and contrast sensitivity tests were established in pre-tests. Any person with a pinhole acuity of less than 6/9, a field defect, an abnormal pupil, an abnormal optic disc, or whose colour or contrast sensitivity tests fell in the range of the poorest 5% of the pre-test population, in either eye, underwent Friedmann field analysis and was referred to one of two ophthalmologists for examination.
The ophthalmologists had a full complement of diag nostic instruments, including slit lamp with lenses and tonometry, and direct and indirect ophthalmoscopes. After a full ophthalmic examination according to a structured protocol, all individuals examined by the ophthalmologist underwent fluorescein angiography, unless they refused such examination or it was contraindicated (by poor general health, pregnancy, young age, etc.).
Partly in order to monitor the sensitivity of the screen ing examination, a computer-generated random sample of individuals was identified. All those in the random sample underwent examination by the ophthalmologist.
Definition o.f Optic Nerve Disease (OND)
A diagnosis of definite OND was made in the presence of marked disc pallor recorded by an ophthalmologist together with defects in visual function and or pupillary light response, or in the presence of active optic neuritis confirmed by fluorescein angiography.
Dosing
At the time of registration each individual was given a unique identifying number. These numbers were allocated sequentially. At the same time each individual was also allocated to one of 30 'treatment groups' (l, 2 ... , 30), again sequentially, each individual's 'treatment group' being pre-printed on his or her registration card. Merck, Sharp and Dohme, manufacturers of ivermectin, provided 30 numbered, but otherwise identical, containers. Fifteen of these containers held ivermectin, the other fifteen a pla cebo. There was no visible difference between the two types of tablet. Merck, Sharp and Dohme allocated iver mectin and placebo to the different containers. Following the completion of the ophthalmic examinations, each indi vidual was weighed to determine how many tablets of ivermectin/placebo should be given. After being given a full explanation of the study in the local language each individual confirmed his or her consent with a thumb-print prior to dosing with tablets from the container corre sponding to the treatment group printed on the registration card, carried out under the supervision of a medical doc tor. The ophthalmologists and ophthalmic nurses were unaware of who received ivermectin and who received placebo. Ivermectin was given at a dosage of 150 /-lg/kg. 
RESULTS
A total of 6831 (87.6%) of the registered population aged 5 years and above underwent the ophthalmic examination. 
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Seven hundred and twenty-six (9.3%) were reported to be absent, 190 (2.4%) refused to participate and 52 (0.7%) were present but not examined, most commonly because they were ill and unable to attend for examination.
Of the 6831 individuals examined, 3420 were allocated to receive ivermectin while 3411 were allocated to receive placebo. The distributions of the ivermectin and placebo groups with regard to age and sex were very similar (Table I ). There was also little difference between the two groups with regard to individual microfilarial loads ( Table I) .
Sensitivity of the Screening Examination
Sensitivity of the screening examination was examined in the random sample. Among those aged 20 years and above, 329 individuals in the random sample were exam ined. Fifty-eight (18%) of these were found to have OND.
All of these individuals had been identified by the ophthal mic nurse screening examinations, suggesting that the screening examination had a high sensitivity (95% con fidence interval 93.6-100%).
Among those examined, a total of 613 (9%) individuals were identified as having probable or definite OND. Of these, 364 (59%) were male and 249 female. The preva lence of OND detected in the random sample was similar to that in the rest of the population (Table 11 ). Thus there is no evidence that the nurses adopted a lower threshold for referral in the random sample because they knew the indi vidual was going to be reviewed by the ophthalmologist.
Active Optic Neuritis
Of the 6831 persons examined, 853 (l}%) had angiog raphy prior to dosing (Table III) . Six individuals, recorded as having pink discs in one or both eyes, did not undergo angiography. In only one of these individuals were the discs thought to be pathological by the ophthalmologists.
This 50-year-old woman had typical clinical signs of florid bilateral optic neuritis and refused all but the most cursory of ophthalmic examinations. She also refused a follow-up examination 7-14 days after dosing.
Sixteen cases of bilateral optic neuritis and 21 of uni lateral optic neuritis were confirmed on angiography, giving a total of 37 cases (prevalence = 0.5%). The distri bution by age and sex of these 37 cases of optic neuritis is shown in Fig. 1 . The median age of the cases was 42 years (range 15-67 years). There were 22 males and 15 females affected.
7-14 Day Follow-up
The ophthalmic nurses re-examined 1956 individuals 271 (82) 58 (18) 329 (100) 7-14 days after dosing (Table IV) . Of the 706 follow-up examinations performed by the ophthalmologists at 7-14 days after dosing 668 were on persons who had been examined by the ophthalmologists prior to dosing. This represented 58% follow-up of the 1150 individuals who were examined by the ophthalmologists prior to dosing. The remaining 38 were individuals whose test results sug gested they had suffered a deterioration in visual function between the two examinations. Of these. 20 were in the ivermectin group and 18 in the placebo group.
Friedmann Fields
A total of 642 individuals had Freidmann visual field analysis before and 7-14 days after dosing. Each quadrant of the right and left fields was recorded as having a defect if 4 or more target points showed diminished sensitivity or 3 or more target points were missed in that quadrant. The results after 7-14 days are shown in Table V by treatment group. As can be seen there was no difference between ivermectin and placebo treated groups. In view of the larger number of improvements compared with deteriorations further analysis was not performed since the learning effect with the test would mask any smaller change of visual field between groups.
Optic Neuritis
A total of 688 angiograms were completed at follow-up with 643 individuals having paired angiograms. Four indi viduals were identified as having developed active optic neuritis during the period since dosing; 2 of these had pre- viously been examined by the ophthalmologists and 2 had passed the screening tests prior to dosing and failed the follow-up examinations. In addition 1 individual had an increase in severity of optic neuritis in one eye. Four of these cases were placebo treated and one ivermectin treated (Table VI) . There were two people in whom the optic neuritis improved over the 7-14 day period as judged by a reduc tion of leakage on fluorescence angiography and improve ment in visual field test results. One of these received ivermectin and the other placebo (Table II) .
459
There were no paired field data on 3 of those patients that deteriorated; in the remaining 3, there were 2 who showed deterioration in their visual field results and the final individual passed all visual field tests on both occasions.
DISCUSSION
The prevalence of OND in mesoendemic onchocercal communities is poorly reported. Anderson et al. 11 looked at those aged 5 years or more and reported a prevalence of 1.7% in hyperendemic savannah popUlations and 2.9% in hyperendemic rain forest popUlations in the Cameroon. Later, however, the same authors reported an incidence of 2.5% and 3. 1 % respectively in the same popUlations over a 5-year period. 1 2 With such a high incidence rate one would expect a higher prevalence than that reported. This could be explained by either a considerable mortality associated To our knowledge this is the first report of the preva lence of active optic neuritis in a population mesoendemic for onchocerciasis. In parallel with our findings for optic atrophy, 1 4 more males than females had active optic neur itis. The highest number of male cases was in the age group 35-44 years whereas the greatest number of female cases was in the age group 45-54 years which parallels an earlier rise in males of the age-specific prevalence of optic atrophy. Our finding of more optic nerve pathology in males than females matches the findings of other groups of higher prevalences of OND and blindness amongst males. 1 0, 1 2 Past reports of the effect of ivermectin therapy on optic neuritis have involved small groups of selected patients and low numbers with OND (Table VII) . None of these studies has suggested an important short-term effect of ivermectin on OND; however, their power to detect such a difference was limited by the small numbers screened and followed-up. The trial reported by Bird et al.6 three-quar ters of individuals with onchocerciasis had acute onset or exacerbation of optic neuritis after taking DEC. With the level of repeated angiography achieved (approximately 300 in each group) and the incidence of active optic neur itis observed in the placebo group, this trial had a power of 90% to detect a 5-fold (or greater) increase in the inci dence of active optic neuritis associated with taking iver mectin. The impact of DEC treatment reported by Bird et al. was considerably greater than this with an incidence rate of 50% associated with treatment with DEC in their specially selected sample with OND. Although we cannot exclude the possibility that ivermectin precipitated or exacerbated optic neuritis in a small number of individuals in our population, our data show no evidence of such an effect. Indeed, in our population ivermectin appears, if anything, to be associated with a lowering in risk. It must, however, be borne in mind that microfilarial loads were lower in our popUlation than in the population studied by Bird et al. Extrapolation of our findings to populations with much heavier infections is problematic.
